Smoking cessation counseling in patients with T2DM and TUD (with obesity)
(Comparision between matched semaglutide vs other anti-diabetes medications cohorts)

Size/cohort	Exposure	Comparison	cases (overall risk) (Exposure)	cases (overall risk) (Comparison)	RD (95% CI)	HR (95% CI)
4,649	semaglutide	insulins	110 (2.4%)	123 (2.6%)	−0.3% (−0.9%, 0.4%)	0.83 (0.64–1.07)
4,652	semaglutide	metformin	112 (2.4%)	135 (2.9%)	−0.5% (−1.1%, 0.2%)	0.83 (0.64–1.06)
3,514	semaglutide	DPP−4i	74 (2.1%)	95 (2.7%)	−0.6% (−1.3%, 0.1%)	0.76 (0.56–1.03)
3,617	semaglutide	SGLT2i	93 (2.6%)	90 (2.5%)	0.1% (−0.6%, 0.8%)	1.01 (0.76–1.35)
4,056	semaglutide	SU	88 (2.2%)	105 (2.6%)	−0.4% (−1.1%, 0.2%)	0.82 (0.62–1.09)
1,609	semaglutide	TZD	32 (2.0%)	29 (1.8%)	0.2% (−0.8%, 1.1%)	1.07 (0.65–1.77)
4,018	semaglutide	other GLP−1RAs	92 (2.3%)	103 (2.6%)	−0.3% (−0.9%, 0.4%)	0.88 (0.67–1.17)

Hazard Ratio (HR)
0.30 0.40 0.60 0.80 1.0 2.0 3.00